Small Cell Lung Cancer (SCLC) . Zepsyre ( Lurbinectedin ) . Oncology Experts Select Top Abstracts Ahead of 2019 ASCO Annual Meeting .

Danielle Ternyila // Tue May 28, 2019 .

Pashtoon M. Kasi, MD, MBBS, MS Ahead of the 2019 Annual ASCO Meeting, several oncology experts spoke with Targeted Oncology to highlight the top abstracts from this year’s meeting that they feel will have the biggest impact on clinical practice.

...

Vivek Subbiah, MD

Precision Medicine

Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

“This is an ATR kinase inhibitor. That is interesting. Small cell lung cancer (SCLC) has always been a challenge, so this is a trial with an agent called lurbinectedin.”

This is a multicenter phase II basket trial investigating the safety and efficacy of lurbinectedin in SCLC with a primary endpoint of confirmed ORR by RECIST v.1.1 criteria. Overall, 105 patients with an ECOG status of 0-2 who had received 1 prior line of chemotherapy received lurbinectedin treatment.

Lurbinectedin is active in the second-line setting for patients with SCLC in both resistant and sensitive disease, according to investigators. The toxicity profile was manageable, demonstrating its potential as a new agent for this patient population.

“That is exciting because for the first time in a long time, we have something that is not a chemotherapy drug that is working in SCLC,” said Subbiah.